Baxter/Hyland Gammagard S.D.
Executive Summary
Solvent detergent treated immune globulin I.V. product approved for the treatment of life-threatening immune disorders such as lymphocytic leukemia and acute idiopathic thrombocytopenic purpura, Baxter reports. The company voluntarily withdrew Gammagard in February ("The Pink Sheet" March 7, T&G-2). In addition to providing greater safety against viral contamination, Gammagard S.D. becomes available in a 10% concentration that allows physicians to administer the product in half the time